Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | CTSV | O60911 | 4/20 | 0.50 |
| ▸ | CTSL | P07711 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31603898 | 1.00 | POLB (0.54) | POLBCTSVCTSLLMNAHTT | |
| SCHEMBL7612096 | 1.00 | POLB (0.54) | POLBCTSVCTSLLMNAHTT | |
| SCHEMBL865598 | 1.00 | POLB (0.54) | POLBCTSVCTSLLMNAHTT | |
| SCHEMBL29858650 | 0.85 | POLB (0.56) | POLBCTSVCTSLLMNAHTT | |
| SCHEMBL4370495 | 0.81 | PDE4A (0.47) | POLBMAPTKMT2ATDP1L3MBTL1 | |
| SCHEMBL2006389 | 0.81 | HPSE (0.49) | POLBLMNAHTTMEN1MAPT | |
| SCHEMBL6478977 | 0.80 | POLB (0.51) | POLBCTSVCTSLLMNAMEN1 | |
| SCHEMBL6328714 | 0.80 | POLB (0.51) | POLBCTSVCTSLLMNAMEN1 | |
| SCHEMBL13898921 | 0.78 | FFAR4 (0.49) | HTTMAPTTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL8768747 | 0.78 | MRGPRX4 (0.51) | HTTMEN1MAPTKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0390762-B1 | New bronchospasmolytic compounds and process for their preparation | DRACO AB (SE) | 1994-01-19 | — | — | EP | claimed |
| EP-0390762-A1 | New bronchospasmolytic compounds and process for their preparation | Aktiebolaget Draco (SE) | 1990-10-03 | — | — | EP | claimed |
| CN-118184536-A | Preparation method of formoterol | 山东新时代药业有限公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-2305635-B1 | FORMOTEROL TARTRATE, PROCESS AND POLYMORPH | SUNOVION PHARMACEUTICALS INC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20150210629-A1 | Process for the Synthesis of Arformoterol | CIPLA LIMITED (IN) | 2015-07-30 | — | — | US | disclosed |
| US-9040559-B2 | BETA2-adrenoceptor agonists | NOVARTIS AG (CH) | 2015-05-26 | — | — | US | disclosed |
| EP-2285770-B1 | PROCESS FOR THE SYNTHESIS OF ARFORMOTEROL | CIPLA LTD (IN) | 2015-05-20 | — | — | EP | disclosed |
| US-9029421-B2 | Process for the synthesis of arformoterol | CIPLA LIMITED (IN) | 2015-05-12 | — | — | US | disclosed |
| US-20140343091-A1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-8796307-B2 | Beta2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2014-08-05 | — | — | US | disclosed |
| US-20140066478-A1 | Beta2-Adrenoreceptor Agonists | NOVARTIS AG (CH) | 2014-03-06 | — | — | US | disclosed |
| US-5965622-A | BRONCHODILATORS; HIGHLY SELECTIVE BETA 2-ADRENERGIC RECEPTOR AGONIST; RESPIRATORY DISORDERS, E.G. ASTHMA, BRONCHITIS; REDUCTION OF A PROTECTED NITRO DERIVATIVE; STEREOSPECIFIC | SEPRACOR INC. (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0938467-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE ISOMERS OF FORMOTEROL | SEPRACOR, INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1998021175-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE ISOMERS OF FORMOTEROL | SEPRACOR, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
| EP-0550612-B1 | NEW PROCESS FOR PREPARING FORMOTEROL AND RELATED COMPOUNDS | ASTRA AB (SE) | 1996-03-06 | — | — | EP | disclosed |
| US-5434304-A | Process for preparing formoterol and related compounds | AKTIEBOLAGET ASTRA (SE) | 1995-07-18 | — | — | US | disclosed |
| EP-0390762-B1 | New bronchospasmolytic compounds and process for their preparation | DRACO AB (SE) | 1994-01-19 | — | — | EP | disclosed |
| EP-0550612-A1 | NEW PROCESS FOR PREPARING FORMOTEROL AND RELATED COMPOUNDS. | ASTRA AB (SE) | 1993-07-14 | — | — | EP | disclosed |
| WO-1992005147-A1 | NEW PROCESS FOR PREPARING FORMOTEROL AND RELATED COMPOUNDS | AKTIEBOLAGET ASTRA (SE) | 1992-04-02 | — | — | WO | disclosed |
| EP-0390762-A1 | New bronchospasmolytic compounds and process for their preparation | Aktiebolaget Draco (SE) | 1990-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210629-A1 | Process for the Synthesis of Arformoterol | ADRB2, REN, AGTR2 | POLB 1341/4885CTSV 926/4885CTSL 2053/4885 |
| US-20140066478-A1 | Beta2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | POLB 2031/4885CTSV 4422/4885CTSL 3319/4885 |
| US-20140343091-A1 | BETA2-ADRENOCEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | POLB 2052/4885CTSV 4085/4885CTSL 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.